1. Scrip
  2. >>New Products

How 2018 Will Affect The Depression Market

 
• By Lucie Ellis-Taitt

Depression therapy has seen little advancement in the last decade but treatment-shifting events are imminent; growth in the depression market will come from sales of new drug classes, including those targeting the NMDA and opioid receptor pathways.

Maple leaves
A year of change: new therapies emerging in depression • Source: Shutterstock

There are several catalysts expected to disrupt the depression market in 2018 including regulatory filings and approvals for potential blockbuster drugs, and key data read outs for therapies to treat postpartum depression (PPD) – a condition that currently has no specifically approved antidepressant treatment.

In the coming year, Johnson & Johnson and Sage Therapeutics Inc. will file their respective depression drugs with regulators in the US and Europe. J&J's esketamine is being...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

Pipeline Watch: Eight Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

More from Scrip

ASCO: IO Continues Climb To Earlier Use With AstraZeneca’s MATTERHORN, BMS’s NIVOPOSTOP

 
• By Mary Jo Laffler

Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

 
• By Alaric DeArment

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.